Literature DB >> 11087714

Human glucocerebrosidase: heterologous expression of active site mutants in murine null cells.

S Fabrega1, P Durand, P Codogno, C Bauvy, C Delomenie, B Henrissat, B M Martin, C McKinney, E I Ginns, J P Mornon, P Lehn.   

Abstract

Using bioinformatics methods, we have previously identified Glu235 and Glu340 as the putative acid/base catalyst and nucleophile, respectively, in the active site of human glucocerebrosidase. Thus, we undertook site-directed mutagenesis studies to obtain experimental evidence supporting these predictions. Recombinant retroviruses were used to express wild-type and E235A and E340A mutant proteins in glucocerebrosidase-deficient murine cells. In contrast to wild-type enzyme, the mutants were found to be catalytically inactive. We also report the results of various studies (Western blotting, glycosylation analysis, subcellular fractionation, and confocal microscopy) indicating that the wild-type and mutant enzymes are identically processed and sorted to the lysosomes. Thus, enzymatic inactivity of the mutant proteins is not the result of incorrect folding/processing. These findings indicate that Glu235 plays a key role in the catalytic machinery of human glucocerebrosidase and may indeed be the acid/base catalyst. As concerns Glu340, the results both support our computer-based predictions and confirm, at the biological level, previous identification of Glu340 as the nucleophile by use of active site labeling techniques. Finally, our findings may help to better understand the molecular basis of Gaucher disease, the human lysosomal disease resulting from deficiency in glucocerebrosidase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087714     DOI: 10.1093/glycob/10.11.1217

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  12 in total

1.  The studies on substrate, product and inhibitor binding to a wild-type and neuronopathic form of human acid-beta-glucosidase.

Authors:  Igor Z Zubrzycki; Agnieszka Borcz; Magdalena Wiacek; Wojciech Hagner
Journal:  J Mol Model       Date:  2007-08-23       Impact factor: 1.810

2.  Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease.

Authors:  Benjamin Liou; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2009-02-13       Impact factor: 4.797

3.  Generation of polyclonal antibodies against recombinant human glucocerebrosidase produced in Escherichia coli.

Authors:  Juliana Branco Novo; Maria Leonor Sarno Oliveira; Geraldo Santana Magalhães; Ligia Morganti; Isaías Raw; Paulo Lee Ho
Journal:  Mol Biotechnol       Date:  2010-11       Impact factor: 2.695

4.  Beta-galactosidase deficiency: an approach to chaperone therapy.

Authors:  Yoshiyuki Suzuki
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

5.  X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease.

Authors:  Hay Dvir; Michal Harel; Andrew A McCarthy; Lilly Toker; Israel Silman; Anthony H Futerman; Joel L Sussman
Journal:  EMBO Rep       Date:  2003-07       Impact factor: 8.807

6.  Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.

Authors:  Junichiro Matsuda; Osamu Suzuki; Akihiro Oshima; Yoshie Yamamoto; Akira Noguchi; Kazuhiro Takimoto; Masayuki Itoh; Yuji Matsuzaki; Yosuke Yasuda; Seiichiro Ogawa; Yuko Sakata; Eiji Nanba; Katsumi Higaki; Yoshimi Ogawa; Lika Tominaga; Kousaku Ohno; Hiroyuki Iwasaki; Hiroshi Watanabe; Roscoe O Brady; Yoshiyuki Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

7.  Glycosylation is crucial for a proper catalytic site organization in human glucocerebrosidase.

Authors:  Laercio Pol-Fachin; Marina Siebert; Hugo Verli; Maria Luiza Saraiva-Pereira
Journal:  Glycoconj J       Date:  2016-03-29       Impact factor: 2.916

8.  In situ visualization of glucocerebrosidase in human skin tissue: zymography versus activity-based probe labeling.

Authors:  Jeroen van Smeden; Irini M Dijkhoff; Richard W J Helder; Hanin Al-Khakany; Daphne E C Boer; Anne Schreuder; Wouter W Kallemeijn; Samira Absalah; Herman S Overkleeft; Johannes M F G Aerts; Joke A Bouwstra
Journal:  J Lipid Res       Date:  2017-10-12       Impact factor: 5.922

9.  Association Between Progranulin and Gaucher Disease.

Authors:  Jinlong Jian; Shuai Zhao; Qing-Yun Tian; Helen Liu; Yunpeng Zhao; Wen-Chi Chen; Gabriele Grunig; Paola A Torres; Betty C Wang; Bai Zeng; Gregory Pastores; Wei Tang; Ying Sun; Gregory A Grabowski; Max Xiangtian Kong; Guilin Wang; Ying Chen; Fengxia Liang; Herman S Overkleeft; Rachel Saunders-Pullman; Gerald L Chan; Chuan-Ju Liu
Journal:  EBioMedicine       Date:  2016-08-04       Impact factor: 8.143

10.  Orthoester functionalized N-guanidino derivatives of 1,5-dideoxy-1,5-imino-d-xylitol as pH-responsive inhibitors of β-glucocerebrosidase.

Authors:  Alen Sevšek; Javier Sastre Toraño; Linda Quarles van Ufford; Ed E Moret; Roland J Pieters; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2017-10-10       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.